Acrisure recently notified investors that it incorrectly embedded financial information within a creditor presentation, putting further pressure on the insurance brokerage’s capital structure, said four sources familiar with the matter.

The once fast-growing company quickly replaced the presentation and urged investors not to rely on the information, but market participants have since been reviewing the disclosure for clues on the future direction of the business.

The embedded information included a forecast that projects Acrisure’s cash flow generation for 2026 will come in under budget, two of the sources said. It also offered a potentially dated outlook for organic growth that showed poor trends in new business and retention, one of the sources added.

The third source said the disclosure has boosted skepticism among some investors who are already on edge about the potential for AI to disrupt the insurance brokerage industry.

Other market participants, though, downplayed the significance of the file.

In the wake of the disclosure, Acrisure’s USD 550m 6.75% secured notes due 2032 tumbled five points to 75 yesterday, per MarketAxess. The USD 925m 8.25% unsecured notes due 2029 traded down four points to 74. The secured notes have since recovered 0.75 points, and the unsecured notes have gone up 0.5 points today, per a trader. Quotes on its USD 4.5bn SOFR+ 300bps term loan due 2030 dropped three points this week to 82.5/84 on Friday, according to Markit.

The company’s debt has been volatile since it reported less-than-stellar 2Q26 numbers a few weeks ago, said the second and a fifth source familiar with the matter. The debt took a further hit reportedly amid concerns over its links to embattled financial group Guggenheim, whose investment arm participated as a minority investor in preferred-equity financings a few years ago.

“Any efforts to turn that into a broader narrative about the company are simply wrong. The relationship is being overstated in a way that doesn’t reflect the facts,” a representative said in a statement at the time.

In the second quarter, Acrisure was negatively impacted by retention pressure in commercial lines and recently lost a team situated in the UK, which may further strain overseas operations, the second and fifth sources said. The North American segment did see almost 4% organic growth, they added.

Prior to the “SaaSpocalypse” at the start of 2026, Acrisure had been gearing up for an IPO this year on the back of its transformation through acquisitions into a diversified fintech platform, as reported.

The company has dialed back expectations on when it will go public and has been working to aggressively cut costs, said three of the sources. Acrisure has projected it will realize over USD 300m in cost savings by the end of 2027, they added.

After a period of not integrating acquisitions, Acrisure is now trying to centralize operations and build its brand as a consumer company, said the first source. He added that the question is whether the company has the time and capital to support a turnaround before it faces a major maturity wall starting in 2029.

In May 2025, Bain Capital led a new USD 2.1bn capital raise of convertible preferred stock with a number of major funds, including existing investor BDT & MSD Partners. The company was valued at USD 32bn at the time, according to a press release.

Morgan Stanley served as placement agent, with Skadden and Varnum serving as legal counsel to Acrisure on the 2025 capital raise.

Acrisure, BDT and Bain did not return requests for comment.